Tags

Type your tag names separated by a space and hit enter

Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit.
Scand J Gastroenterol 2007; 42(12):1428-33SJ

Abstract

OBJECTIVE

Circulating antibodies against naive, whole gliadin have been replaced by more accurate endomysial and tissue transglutaminase antibody tests in the diagnosis of coeliac disease. The purpose of this study was to compare these serological tests with a new test recognizing antibodies against deamidated and defined gliadin peptides.

MATERIAL AND METHODS

The study population comprised selected coeliac disease patients in a tertiary clinic: newly detected patients before and after a gluten-free diet, patients with persistent small-bowel mucosal villous atrophy despite a strict gluten-free diet and non-coeliac controls reporting abdominal symptoms after ingestion of cereals. Comparisons were made between serum IgA-class gliadin peptide, endomysial, tissue transglutaminase and conventional gliadin antibodies.

RESULTS

The deamidated gliadin peptide antibody test showed a sensitivity of 91% and a specificity of 98% in coeliac disease. The tissue transglutaminase antibody test performed equally well. The specificity of endomysial antibody was just as high, but its sensitivity was lower, 80%. The conventional gliadin antibody test showed poor sensitivity and specificity. Combination of the deamidated gliadin peptide and tissue transglutaminase tests offered the best sensitivity without loss of specificity in the diagnosis of coeliac disease. All antibody levels declined in line with mucosal recovery. The deamidated gliadin peptide antibody test showed six of the nine cases with small-bowel mucosal damage persisting on a gluten-free diet, whereas tissue transglutaminase detected only two cases and endomysial antibody none.

CONCLUSIONS

The new gliadin peptide antibody test proved highly accurate in the diagnostic work-up and follow-up of coeliac disease and can be endorsed in combination with the tissue transglutaminase test.

Authors+Show Affiliations

Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Finland. katri.kaukinen@uta.fiNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17852878

Citation

Kaukinen, Katri, et al. "Resurrection of Gliadin Antibodies in Coeliac Disease. Deamidated Gliadin Peptide Antibody Test Provides Additional Diagnostic Benefit." Scandinavian Journal of Gastroenterology, vol. 42, no. 12, 2007, pp. 1428-33.
Kaukinen K, Collin P, Laurila K, et al. Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit. Scand J Gastroenterol. 2007;42(12):1428-33.
Kaukinen, K., Collin, P., Laurila, K., Kaartinen, T., Partanen, J., & Mäki, M. (2007). Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit. Scandinavian Journal of Gastroenterology, 42(12), pp. 1428-33.
Kaukinen K, et al. Resurrection of Gliadin Antibodies in Coeliac Disease. Deamidated Gliadin Peptide Antibody Test Provides Additional Diagnostic Benefit. Scand J Gastroenterol. 2007;42(12):1428-33. PubMed PMID: 17852878.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit. AU - Kaukinen,Katri, AU - Collin,Pekka, AU - Laurila,Kaija, AU - Kaartinen,Tanja, AU - Partanen,Jukka, AU - Mäki,Markku, PY - 2007/9/14/pubmed PY - 2008/6/18/medline PY - 2007/9/14/entrez SP - 1428 EP - 33 JF - Scandinavian journal of gastroenterology JO - Scand. J. Gastroenterol. VL - 42 IS - 12 N2 - OBJECTIVE: Circulating antibodies against naive, whole gliadin have been replaced by more accurate endomysial and tissue transglutaminase antibody tests in the diagnosis of coeliac disease. The purpose of this study was to compare these serological tests with a new test recognizing antibodies against deamidated and defined gliadin peptides. MATERIAL AND METHODS: The study population comprised selected coeliac disease patients in a tertiary clinic: newly detected patients before and after a gluten-free diet, patients with persistent small-bowel mucosal villous atrophy despite a strict gluten-free diet and non-coeliac controls reporting abdominal symptoms after ingestion of cereals. Comparisons were made between serum IgA-class gliadin peptide, endomysial, tissue transglutaminase and conventional gliadin antibodies. RESULTS: The deamidated gliadin peptide antibody test showed a sensitivity of 91% and a specificity of 98% in coeliac disease. The tissue transglutaminase antibody test performed equally well. The specificity of endomysial antibody was just as high, but its sensitivity was lower, 80%. The conventional gliadin antibody test showed poor sensitivity and specificity. Combination of the deamidated gliadin peptide and tissue transglutaminase tests offered the best sensitivity without loss of specificity in the diagnosis of coeliac disease. All antibody levels declined in line with mucosal recovery. The deamidated gliadin peptide antibody test showed six of the nine cases with small-bowel mucosal damage persisting on a gluten-free diet, whereas tissue transglutaminase detected only two cases and endomysial antibody none. CONCLUSIONS: The new gliadin peptide antibody test proved highly accurate in the diagnostic work-up and follow-up of coeliac disease and can be endorsed in combination with the tissue transglutaminase test. SN - 0036-5521 UR - https://www.unboundmedicine.com/medline/citation/17852878/Resurrection_of_gliadin_antibodies_in_coeliac_disease__Deamidated_gliadin_peptide_antibody_test_provides_additional_diagnostic_benefit_ L2 - http://www.tandfonline.com/doi/full/10.1080/00365520701452217 DB - PRIME DP - Unbound Medicine ER -